Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder

Journal of Immunotherapy

Volumn 40, Issue 3, 2017, Pages 114-116

  Chang, Elaine ^a,b   Sabichi, Anita L ^a,b   Sada, Yvonne H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

checkpoint inhibitor; immune related adverse events; myasthenia gravis; squamous cell carcinoma of bladder

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINERGIC RECEPTOR ANTIBODY; CYTOKERATIN 7; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN; NIVOLUMAB; PYRIDOSTIGMINE; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR GATA 3; UROPLAKIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL GAS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CRANIAL NERVE PARALYSIS; CYSTOSCOPY; DIPLOPIA; DYSPHAGIA; DYSPNEA; FATIGUE; FINE NEEDLE ASPIRATION BIOPSY; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; LAPAROSCOPIC SURGERY; LUNG NODULE; LYMPH NODE DISSECTION; MALE; MAXIMAL INSPIRATORY PRESSURE; MYASTHENIA GRAVIS; NEPHROURETERECTOMY; NERVE STIMULATION; NONINVASIVE VENTILATION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PTOSIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URETER; WEAKNESS; WEDGE RESECTION; ADVERSE DRUG REACTION; BLADDER TUMOR; FATALITY; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, SQUAMOUS CELL; DIPLOPIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DYSPNEA; FATAL OUTCOME; HUMANS; IMMUNOTHERAPY; MALE; MYASTHENIA GRAVIS; PROGRAMMED CELL DEATH 1 RECEPTOR; URINARY BLADDER NEOPLASMS;

EID: 85013745159     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000161     Document Type: Article

References (15)

1. Seretta V, Pomara G, Piazza F, et al. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol. 2000;37:85-89.
2. Sharma P, Bono P, Kim JW, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): results from the phase I/II CheckMate 032 study. J Clin Oncol. 2016;34 suppl:4501. Abstract.
3. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210-225.
4. Nishimura H, Nose M, Hiai H, et al. Development of lupuslike autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
5. Alnahhas I, Wong J. A case of new onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve. 2016. [Epub ahead of print]. Doi:10.1002/mus.25496.
6. Lau KH, Kumar A, Yang IH, et al. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157-161.
7. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52: 307-308.
8. Lopez D, Calvo A, Fershko A. Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature. Br J Med Health Res. 2015;2:11-16.
9. Maeda O, Yokota K, Atsuta N, et al. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78:119-122.
10. Phadke SD, Ghabour R, Swick BL, et al. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316.
11. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small cell lung cancer. Muscle Nerve. 2016;54:507.
12. Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 2016;54:507-509.
13. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46:86-88.
14. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54:506-507.
15. Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016; 13:118-131.